Sarpatwari A, Mahesri M, Lii J, Lee SB, Zakoul H, Toyserkani GA, Zhou EH, LaCivita C, Dal Pan GJ, Bykov K, Moran L, Avorn J, Kesselheim AS, Huybrechts KF - BMJ Mental Health
- Research Publications
- Regulation and Clinical Evidence
Summary:
Clozapine initiators had a markedly higher relative risk of neutropenia-related hospitalization than olanzapine initiators, especially within the first 6 months after initiation, though absolute risks were very low. The findings help contextualize FDA’s 2025 decision to remove the clozapine risk evaluation and mitigation strategy (REMS) while reinforcing the importance of continued monitoring for neutropenia in patients taking clozapine.
VIEW SOURCE
Recent Work from PORTAL
How Congress Can Fix Expert Advisory Committees
Daval CJR, Kesselheim AS - STAT
- Commentary & Opinion
- Regulation and Clinical Evidence
International Regulatory Status and Reimbursement Recommendations of Haematological Malignancy Drugs Withdrawn from the FDA Accelerated Approval Pathway
Mulsant SS, Kesselheim AS, Naci H - Journal of Cancer Policy
- Research Publications
- Price, Value, and Access
- Regulation and Clinical Evidence
Comments on FDA Discussion Paper, “Considerations for the Regulation of Generative AI-Enabled Medical Devices”
Jaiswal N, Gorijavolu R, Thomas S, Hwang TJ, Celi LA, Kesselheim AS - Food and Drug Administration (FDA)
- Policy Interactions
- Regulation and Clinical Evidence
Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital • Harvard Medical School
41 Avenue Louis Pasteur, Suite 0B17, Boston, MA 02115
©2026 Program On Regulation, Therapeutics, And Law (PORTAL). All rights reserved.